API
< Back to situations

[ORGANIZATION]

tirzepatide

Featured in 25 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [GB] [DE]

Expanding therapeutic uses and regulatory concerns for GLP-1

43 clusters · 180 sources · last updated

Latest: Semaglutide study shows BMI reduction in children with obesity

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

[ACTIVE] [HEALTH] [KR] [JP]

South Korea obesity and diabetes medication regulation

4 clusters · 20 sources · last updated

Latest: South Korea establishes task force to crack down on illegal obesity drug sales

In late October 2026, the South Korean Ministry of Food and Drug Safety expanded the approved indications for Mounjaro (tirzepatide). The medication is now approved for adult type 2 diabetes patients with established car

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

343 clusters · 1318 sources · last updated

Latest: FDA issues warning for GLP-1 drugs over vision loss risks

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt

[QUIET] [HEALTH] [US] [AR] [CA]

Eli Lilly EloraTZP and retatrutide obesity drug clinicals

4 clusters · 38 sources · last updated

Latest: Eli Lilly's retatrutide outperforms Ozempic in weight loss trial

Eli Lilly has reported results from Phase 2b clinical trials for EloraTZP, a combination therapy involving eloralinantide and tirzepatide designed to treat obesity and type 2 diabetes. Data indicates the combination tar

[QUIET] [HEALTH] [BR] [PY] [FR]

Brazil ANVISA expands product safety enforcement

43 clusters · 290 sources · last updated

Latest: Anvisa bans Accu-Chek Active glucose test strips on Amazon

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

Also covered in